Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA™ (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)
VIVJOA is a new option for postmenopausal and permanently infertile women with recurrent vulvovaginal candidiasis (RVVC) VIVJOA is now available in a network of partner pharmacies that includes mail order and local pickup options DURHAM, N.C.–(BUSINESS WIRE)–Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs … [Read more…]
